Morinaga Milk Industry Co., Ltd.

The Green Cross Corporation

Tokai Bussan Co., Ltd.

Nobuya Yanai

Muneo Yamada

Morio Kuboyama

Katsuhiro Ogasa

Fumimaro Takaku

Satoshi Funakoshi

Masayuki Nishida

Hajime Yokota

Nobuhiro Yamada

Minoru Saito

Takuji Kawashima

Shinya Suzu

Kazuo Morimoto

Kazuo Motoyoshi

Satoshi Kanazawa

Yoshiteru Watanabe

Katsuo Yoshida

Shigenobu Shiotani

Kunio Ujiie

An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or sodium L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof obtained from animal extract as an agent for scavenging hypochlorite active oxygen.

Antioxidant constituents

Human M-CSF preparations and recombinant human M-CSF preparations against myelodysplastic syndrome, malignant tumor and hyperlipemia and auxiliary therapeutic preparations to be dosed along with platinum-complex anticancer preparations.

Human monocyte-macrophage-CSF preparations

Human urine-origin colony-stimulating factor and kallikrein are separated in pure form, respectively, from an aqueous solution thereof, such as a urinary protein-concentrated solution by subjecting the solution added with a stabilizer such as octyl-phenoxypolyethoxyethanaol or polyethylene glycol both having a molecular weight of 1,000-10,000, to high-performance gel filtration effective in molecular exclusive limit of 10.sup.5 -5.times.10.sup.5 as determined with globular protein.

Method of preparation of human urine origin colony-stimulating factor

A colony stimulating factor effective in treating human granulocytopenia is produced by cultivating monocytes and macrophages isolated from the human peripheral blood in a synthetic medium for tissue culture containing a glycoprotein isolated from human urine and capable of stimulating the formation of human granulocytes or mouse macrophages and granulocytes.

Method for producing substance capable of stimulating differentiation

A colony-stimulating factor having definite physical and chemical properties and a function of stimulating activity on human bone marrow cells to proliferate and differentiate, thereby forming granulocyte colonies, is obtained from human urine by concentrating the urine with respect to proteins contained therein by adsorption chromatography with silica gel, salting out with ammonium sulfate and other means, then removing impurities by adsorption on cation exchanger, and further purifying by ion exchanging chromatography on anion exchanger, gel filtrating chromatography with highly crosslinked gels, affinitive chromatography with sugar affinitire adsorbents and electrophoresis.

HGI-Glycoprotein capable of stimulating proliferation and

A colony-stimulating factor having definite physical and chemical properties and a function of stimulating activity on human bone marrow cells to proliferate and differentiate, thereby forming granulocyte colonies, is obtained from human urine by concentrating the urine with respect to proteins contained therein by adsorption chromatography with silica gel, salting out with ammonium sulfate and other means, then removing impurities by adsorption on cation exchanger, and further purifying by ion exchanging chromatography on anion exchanger, gel filtrating chromatography with highly crosslinked gels, affinity chromatography with sugar affinitive adsorbents and electrophoresis. This substance is stable in the presence of a stabilizer such as albumin or urinary proteins, against heat-treatment of virus-inactivation and can be used as a leukopenia curative which is precluded from fear of virus-infection.

Virus-inactivated HGI-glycoprotein capable of stimulating proliferation

Growing community of inventors

Tokyo, Japan

Nobuya Yanai